National Vision Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $EYE in the last 7 days.
No SEC Form 4 filings for $EYE in the last 30 days.
See all $EYE insider activity →National Vision Holdings (EYE) reported Q2 2026 net revenue of $498.8M, up 2.5%, with adjusted EPS of $0.25. Adjusted comp sales grew 2.2%, offset by a 4.9% traffic decline due to e-commerce replatforming. The company narrowed its full-year revenue guidance to $2.037B-$2.076B, citing traffic dynamics. Management highlighted a shift toward premium products and cost efficiencies.
EyePoint’s shares fell over 70% after its phase 3 readout for Duravyu, a drug-device combo for wet age-related macular degeneration, missed a primary endpoint versus Regeneron’s Eylea. EyePoint cited non-wAMD related vision loss in 9 of 211 patients and said an ad hoc analysis showed non-inferiority. Lucia trial is due this fall.
National Vision Holdings (Nasdaq: EYE) reported Q2 net revenue up 2.5% to $498.8 million and net income of $12.4 million versus $8.7 million. Diluted EPS rose to $0.15 from $0.11, and adjusted operating income increased 32.7% to $31.6 million. The company raised its 2026 adjusted operating income outlook to $119-$139 million from $107-$133 million.
Recent EYE coverage spans earnings, market movers and corporate actions.
EYE reported modest revenue growth and improved margins, with guidance indicating a tighter revenue range but higher operating income.
Duravyu’s first phase 3 readout miss materially raises FDA approval risk and increases uncertainty for the upcoming Lucia trial.
Higher-value customer mix and cost discipline drove a profitability beat and an upward 2026 outlook, supporting a bullish repricing bias.
Q2 call provides fresh full-year revenue, EPS, operating income, and capex guidance plus a quantified e-commerce replatforming headwind.
The article frames today’s pre-open move as a fresh earnings-and-guidance catalyst, with macro CPI timing adding near-term volatility risk.
alphai scores every news story that mentions EYE with an AI model for sentiment and relevance, and aggregates insider trades from National Vision Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
National Vision Holdings (EYE) reported Q2 2026 net revenue of $498.8M, up 2.5%, with adjusted EPS of $0.25. Adjusted comp sales grew 2.2%, offset by a 4.9% traffic decline due to e-commerce replatforming. The company narrowed its full-year revenue guidance to $2.037B-$2.076B, citing traffic dynamics. Management highlighted a shift toward premium products and cost efficiencies.
3 min readEyePoint’s shares fell over 70% after its phase 3 readout for Duravyu, a drug-device combo for wet age-related macular degeneration, missed a primary endpoint versus Regeneron’s Eylea. EyePoint cited non-wAMD related vision loss in 9 of 211 patients and said an ad hoc analysis showed non-inferiority. Lucia trial is due this fall.
6 min readNational Vision Holdings (Nasdaq: EYE) reported Q2 net revenue up 2.5% to $498.8 million and net income of $12.4 million versus $8.7 million. Diluted EPS rose to $0.15 from $0.11, and adjusted operating income increased 32.7% to $31.6 million. The company raised its 2026 adjusted operating income outlook to $119-$139 million from $107-$133 million.
3 min readNational Vision (NASDAQ:EYE) reported positive managed-care comparable sales growth, citing traffic and ticket gains and growth in anti-reflective, transition, polycarbonate and premium progressive lenses. The company said e-commerce replatforming reduced adjusted comparable-store sales by about 150 bps in Q2. Outlook: net revenue $2.03B-$2.08B, adjusted comp sales +3%-5%, adjusted operating income $119M-$139M, adjusted EPS $0.94-$1.09.
6 min readNational Vision Holdings shares rose 1.9% in pre-open trading after the company reported Q2 2026 results. Analysts expected about $0.18 EPS on ~$499.84M revenue, versus Q1 adjusted EPS of $0.45 and 6.6% YoY revenue growth. The firm reaffirmed full-year 2026 EPS guidance of $0.85 to $1.09 and filed an 8-K. The earnings call coincided with the U.S. CPI release.
4 min readNational Vision Holdings, Inc. (EYE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 National Vision Holdings, Inc. Reports Second Quarter 2026 Financial Results Strategic Transformation Delivers Accelerated Profitability Raises Full-Year Adjusted Operating Income and Tightens Adjusted Comparable Store Sales Growth Outlook Second quarter 2026 highlig
6 min readItaconix (ITX) raised 2026 revenue guidance to at least $14.8m from $13.3m after H1 revenues rose 72% to $8.3m. It expects 2026 gross margin of 36% and said guidance supports breakeven and investment. Eagle Eye (EYE) reported FY26 results ahead of expectations, with ARR up 31% to £44.5m. Alumasc (ALU) suspended CEO Pamela Bingham and trimmed forecasts.
6 min readEagle Eye Solutions (LON:EYE) shares rose 7.5% after the loyalty and promotions platform provider said it expects a return to double-digit revenue and EBITDA growth in fiscal year 2027. The company attributed the outlook to higher annual recurring revenue and new customer acquisitions, and reiterated targets of over £100 million revenue and EBITDA margin above 30%.
2 min readEagle Eye Solutions said annual recurring revenue rose 31% year over year to £44.5 million for FY2026, driven by new customer contracts and its OEM partnership. Total revenue increased 21% to £46.1 million, excluding a lost NRS contract. Adjusted EBITDA was £9.8 million. FY2027 targets double-digit revenue and EBITDA growth.
4 min readNational Vision Holdings, Inc. (EYE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. eye-20260617 0001710155 false 0001710155 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 8-K ________________________________________________________________
2 min read
